Abstract
Neoadjuvant chemotherapy is able to reduce the size of the majority of breast tumours and down-stage axillary-node status. The aim of this study was to assess the prognostic value of persistent node involvement after neoadjuvant chemotherapy. A total of 488 patients with T2–T3, N0–N1 breast cancer treated by neoadjuvant chemotherapy followed by tumour excision and axillary lymph-node dissection between 1981 and 1992 were selected from the Institut Curie database. Median follow-up was 7 years. Overall objective response rate before local treatment was 52% and breast tumour size was reduced in 83% of patients. No pathologic nodal involvement was observed in 46.5% of patients. Patients with ≥ eight positive nodes had a very poor median disease-free survival of only 20 months. Their 10-year disease-free survival rate was 7%, while the 10-year disease-free survival rate for patients with no node involvement was 64%. Median survival for patients with ≥ eight nodes positive was 48 months and the 10-year survival rate was 26% (P < 0.0001). On multivariate analysis, outcome was strongly correlated with pathological nodal status, tumour grade, hormonal receptor status and clinical response of the tumour. In conclusion, patients with extensive nodal involvement after neoadjuvant chemotherapy have a very poor outcome. Second-line treatment should be considered in this population. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bhalla K and Harris WB (1998 Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol 25(suppl. 3): 19–24
Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M and Zambetti M (1998 Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100
Botti C, Vici P, Lopez M, Scinto AF, Cognetti F and Cavaliere R (1995 Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 181: 202–208
Cameron DA, Anderson ED, Levack P, Hawkins RA, Anderson TJ, Leonard RC, Forrest AP and Chetty U (1997 Primary systemic therapy for operable breast cancer – 10-year survival data after chemotherapy and hormone therapy. Br J Cancer 76: 1099–1105
Carter CL, Allen C and Henson DE (1989 Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181–187
Colleoni M, Orvieto E, Nolé F and Orlando L (1999 Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35: 574–579
Costa SD, von Minckwitz G, Raab G, Blohmer JU, Dresel V, Eidtmann H, Hilfrich J, Jackisch C, Merkle E, Gademann G and Kaufmann M (1999 The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 26: 24–31
Cox DR (1972 Regression models and life tables (with discussion). J Stat Soc B 34: 187–220
Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, Sacks N and McKinna J (1998 Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16: 107–114
Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, Poisson R, Shibata H and Volk H (1983 Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551–1557
Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW and Dimitrov NV (1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV and Bear HD (1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685
Frye D, Buzdar A and Hortobagyi G (1995 Prognostic significance of axillary involvement after preoperative chemotherapy in stage III breast cancer. Proc Am Soc Clin Oncol 14: 95
Gardin G, Rosso R, Campora E, Repetto L, Naso C, Canavese G, Catturich A, Corvo R, Guenzi M, Pronzato P, Baldini E and Conte PF (1995 Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 31A: 1428–1433
Haagensen CD (1977 Treatment of curable carcinoma of the breast. Int J Radiat Oncol Biol Phys 2: 975–980
Hutcheon AW, Smith IC, Heys SD, Ogston KN, Miller ID, Payne S, Eremin O, Ah-See AK, Eggleton P and Group TAB (2000 Primary chemotherapy in breast cancer: significantly enhanced clinical and pathological response with docetaxel. Proc Am Soc Clin Oncol 19,
Jain V, Landry M and Levine EA (1996 The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 62: 162–165
Kaplan EL and Meier P (1958 Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S and Beitsch P (1998 The sentinel node in breast cancer – a multicenter validation study. N Engl J Med 339: 941–946
Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN and Singletary SE (1998 Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176: 502–509
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE 1999a Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [see comments]. J Clin Oncol 17: 460–469
Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN and Singletary SE 1999b Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230: 72–78
MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I and Coindre JM (1996 Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458–1465
Machiavelli MR, Romero AO, Perez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Romero Acuna LA, Romero Acuna JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT and Leone BA (1998 Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4: 125–131
Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK and Allred DC (1997 Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593–600
Mamounas EP (1998 Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 25: 31–35
Mantel N (1966 Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170
Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM and Bonichon F (1999 Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47–52
McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU and Balch CM (1989 The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124: 21–225
Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH and Murphy GP (1980 Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45: 2917–2924
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP (1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655
Powles TJ, Hickish TF, Makris A, Ashley SE, O’Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I and Ford HT (1995 Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547–552
Pusztai L and Hortobagyi GN (1998 Discouraging news for high-dose chemotherapy in high-risk breast cancer. Lancet 352: 501–502
Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H and Pouillart P (1989 Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383–1387
Remvikos Y, Mosseri V, Zajdela A, Fourquet A, Durand JC, Pouillart P and Magdelenat H (1993 Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci 698: 193–203
Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP and Baloch Z (1995 Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297–306
Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC and Pouillart P (1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645–652
Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangie T, Remvikos Y, Durand JC, Fourquet A and Pouillart P (1995 Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A: 1969–1975
Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM and Chepic OF (1994 Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5: 591–595
Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, McKinna JA and Baum M (1995 High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424–429
Valagussa P, Bonadonna G and Veronesi U (1978 Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41: 1170–1178
Author information
Authors and Affiliations
Additional information
Pathology Department, Institut Curie, 26 Rue d'Ulm, Paris Cedex 05, 75248, France
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pierga, JY., Mouret, E., Diéras, V. et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83, 1480–1487 (2000). https://doi.org/10.1054/bjoc.2000.1461
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1461
Keywords
This article is cited by
-
18F-FDG PET/CT-based deep learning radiomics predicts 5-years disease-free survival after failure to achieve pathologic complete response to neoadjuvant chemotherapy in breast cancer
EJNMMI Research (2023)
-
Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
Scientific Reports (2021)
-
New horizons in imaging and surgical assessment of breast cancer lymph node metastasis
Breast Cancer Research and Treatment (2021)
-
Radiation recall dermatitis induced by trastuzumab
Breast Cancer (2016)
-
FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients
European Journal of Nuclear Medicine and Molecular Imaging (2011)